Abstract
Objective: Standard therapy for advanced epithelial ovarian cancer (EOC) is surgical cytoreduction followed by six cycles of carboplatin and paclitaxel (CT). Randomized, phase III controlled studies have shown significant improvement in progression-free survival (PFS) with consolidation paclitaxel (T) and bevacizumab (B). We sought to evaluate the cost-effectiveness (C/E) of consolidation T versus B in the treatment of advanced EOC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
